Several committees have been established to provide advice to the Chief Executive Officer on relevant matters related to organ and tissue donation and transplantation in Australia.
Following is a list of the Authority's committees, their membership and their functions.
The Audit Committee
The Audit Committee, a central governance element for the Authority, was established by the Authority's Chief Executive Officer in accordance with section 46 of the FMA Act and the Financial Management and Accountability Orders 2.1.1 and 2.1.2.
The role of the Audit Committee is to provide independent assurance and assistance to the Chief Executive Officer to meet the Authority's responsibilities under the FMA Act, particularly in relation to risk control, compliance frameworks and external accountabilities.
The Audit Committee comprises the Chief Executive Officer, the Chief Financial Officer and three external members.
State Medical Directors and Jurisdictional Working Group Committee
The State Medical Directors and Jurisdictional Working Group Committee is the premier governance committee for the DonateLife Network. The committee comprises State Medical Directors (SMD) and jurisdictional health department representatives, and is chaired by the CEO.
This group considers and makes recommendations to the CEO in respect of the strategic priorities, clinical and data governance, planning and leadership of the DonateLife Network, and the implementation at a state-based level of the Australian Government's national reform agenda on organ and tissue donation.
Clinical Governance Committee
The premier clinical committee for the DonateLife Network is the Clinical Governance Committee, chaired by the National Medical Director, which is pursuing specific clinical issues relevant to the work of the DonateLife Network. The committee comprises State Medical Directors (SMD) and Agency Managers from each State and Territory, the National Medical Director and the CEO.
One of the key tasks of this committee will be to progress the opportunities for enhancement as identified in the Mid-Point Implementation Review Report, the main task being the development of a Clinical Governance Framework.
